

Presented by:

Therapeutic Radiology Grand Rounds

Combining Immunotherapy & Radiation Therapy in Stage III Non- Small Cell Lung Cancer

4/21/2022 9:00:00 AM-4/21/2022 10:00:00 AM | Medical Campus

Weekly grand rounds necessary and essential to the education mission of the department for trainees and peers at the faculty level on the latest developments as well as a forum for discussion on the latest cases to promote group input.

Texting code for today's session: 26755

Faculty:

Salma Jabbour, MD, FASTRO Professor, Vice Chair of Clinical Research & Faculty Development; Clinical Chief of the Radiation Oncology Clinic at RWJBH Rutgers Cancer Institute of New Jersey

Program Goal:

1 Appraise the biological mechanisms underlying the application of immune checkpoint inhibitors in the context of radiotherapy in the treatment of Stage III NSCLC

2 Evaluate reported clinical trials that evaluated the role of immune checkpoint inhibitors in the treatment of Stage III NSCLC

3 Study information about characteristics and incidence of pneumonitis from radiation, immune checkpoint inhibitors, and combinations

Target Audience: Oncology

Financial Disclosure Information:

Accreditation Statement: Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Salma Jabbour, MD, FASTRO, faculty/planner for this educational activity is a consultant for Merck

Henry S. Park, MD, MPH, faculty planner for this educational event is Honorarium Speaker for Bristol Myers Squibb

All of the relevant financial relationships listed for this individual have been mitigated.

Designation Statement: Yale School of Medicine designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 Credit(s) \mathbb{M} . Physicians should only claim credit commensurate with the extent of their participation in the activity.

For questions, email lisa.zucaro@yale.edu.



www.cme.yale.edu